Skip to main content

Summary

Reproductive hormones are central to women's aging but remain difficult to incorporate into population research because assays are costly and hormone concentrations can vary substantially depending on the timing of sample collection within the menstrual cycle. Together, assay costs and uncertainty about optimal sample timing have limited the inclusion of reproductive hormone measures in population-based studies, particularly during the menopausal transition. This pilot study will recruit 50 menstruating midlife women to measure anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), and estradiol (E2) during the early follicular, mid-cycle, and late luteal phases. We will quantify within- and between-person variability, evaluate how hormone concentrations differ across cycle phases, and examine whether variability is associated with age, cycle regularity, and perimenopausal symptoms. Analyses will incorporate the observed timing of each blood draw relative to menstrual bleeding and estimated ovulation, allowing us to assess the consequences of deviations from idealized collection windows. By establishing the feasibility and interpretability of cycle-anchored hormone measurement under realistic research conditions, this study will provide preliminary estimates needed to design larger investigations of endocrine reproductive aging. Ultimately, the findings will strengthen the use of reproductive hormones as biomarkers of reproductive aging and improve their integration into population-based studies of women's aging and health.

Project Details

Key People
Funding Source
Project Dates
Project Status
Research Themes
Countries